These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 12960608

  • 1. Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications.
    Antovic JP, Yngen M, Ostenson CG, Antovic A, Wallen HN, Jorneskög G, Blombäck M.
    Blood Coagul Fibrinolysis; 2003 Sep; 14(6):551-6. PubMed ID: 12960608
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
    Antovic JP, Schulman S, An SS, Greenfield RS, Blombäck M.
    Scand J Clin Lab Invest; 2004 Sep; 64(8):745-51. PubMed ID: 15719893
    [Abstract] [Full Text] [Related]

  • 4. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.
    Antovic J, Schulman S, Eelde A, Blombäck M.
    Haemophilia; 2001 Nov; 7(6):557-60. PubMed ID: 11851753
    [Abstract] [Full Text] [Related]

  • 5. Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII.
    Antovic JP, Antovic A, He S, Tengborn L, Blombäck M.
    Haemophilia; 2002 Nov; 8(6):781-6. PubMed ID: 12410647
    [Abstract] [Full Text] [Related]

  • 6. Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay.
    Antovic JP, Antovic A.
    Thromb Haemost; 2003 Oct; 90(4):620-7. PubMed ID: 14515182
    [Abstract] [Full Text] [Related]

  • 7. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
    Miljić P, Heylen E, Willemse J, Djordjević V, Radojković D, Colović M, Elezović I, Hendriks D.
    Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():74-8. PubMed ID: 20229688
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
    Incampo F, Carrieri C, Galasso R, Scaraggi FA, Di Serio F, Woodhams B, Semeraro N, Colucci M.
    J Thromb Haemost; 2013 Feb; 11(2):315-24. PubMed ID: 23256818
    [Abstract] [Full Text] [Related]

  • 10. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

  • 11. Plasma thrombin-activatable fibrinolysis inhibitor levels in children and adolescents with type 1 diabetes mellitus: possible relation to diabetic microvascular complications.
    Sherif EM, Elbarbary NS, Abd Al Aziz MM, Mohamed SF.
    Blood Coagul Fibrinolysis; 2014 Jul; 25(5):451-7. PubMed ID: 24509335
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
    Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H.
    Thromb Res; 2001 Oct 01; 104(1):1-6. PubMed ID: 11583733
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice.
    Mao SS, Holahan MA, Bailey C, Wu G, Colussi D, Carroll SS, Cook JJ.
    Blood Coagul Fibrinolysis; 2005 Sep 01; 16(6):407-15. PubMed ID: 16093731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.